8-K: Foghorn Therapeutics Announces Third Quarter 2024 Financial Results and Pipeline Progress

Foghorn Therapeutics reported its third quarter 2024 financial results, highlighted by the first patient dosed with FHD-909 and advancements in multiple clinical and preclinical programs.

Summary

• Foghorn Therapeutics announced its financial results for the third quarter of 2024, with a net loss of $19.1 million, compared to a net loss of $14.3 million for the same period in 2023.
• Collaboration revenue was $7.8 million, down from $17.5 million in the prior year due to the conclusion of a Merck collaboration.
• Research and development expenses decreased to $24.7 million from $26.3 million year-over-year.
• The company's cash, cash equivalents, and marketable securities totaled $267.4 million as of September 30, 2024, providing a cash runway into 2027.
• The first patient was dosed with FHD-909, a selective SMARCA2 inhibitor, in a Phase 1 trial targeting SMARCA4 mutated cancers.
• Topline Phase 1 data for FHD-286 in combination with decitabine for AML is expected by year-end 2024.
• IND-enabling studies for the Selective CBP degrader program are on track to begin by year-end 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the clinical advancements and strong cash position, but tempered by the increased net loss and decreased collaboration revenue.

Positives

• The company has a strong cash position of $267.4 million, providing a cash runway into 2027.
• The first patient was dosed with FHD-909, marking a significant milestone for the program.
• The company is advancing multiple programs, including FHD-286, CBP degrader, and EP300 degrader, towards clinical development.
• Preclinical data for the CBP degrader program shows robust anti-tumor activity without significant toxicity.
• The company has identified potent and selective EP300 degraders with anti-tumor activity.
• Foghorn has identified selective ARID1B binders, a critical step towards developing a degrader.

Negatives

• Collaboration revenue decreased to $7.8 million from $17.5 million in the same quarter of the previous year due to the end of the Merck collaboration.
• The net loss increased to $19.1 million from $14.3 million in the same quarter of the previous year.

Risks

• The company's forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Actual results may differ materially from those contemplated by the forward-looking statements due to various factors, including market conditions and clinical trial outcomes.
• The company is dependent on its CDMOs and CROs for manufacturing and research needs.
• There are risks associated with obtaining regulatory approval for FHD-286, FHD-909, and any future product candidates.
• The company faces competition from other companies in the biotechnology industry.

Future Outlook

The company expects topline data from the FHD-286 combination study in AML by year-end 2024 and plans to initiate IND-enabling studies for the Selective CBP degrader program by the same time. They also anticipate a cash runway into 2027.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that they continue to advance their pipeline of multiple therapeutics targeting novel biology in the chromatin regulatory system.
• Adrian Gottschalk mentioned that they look forward to further clinical progress with the FHD-909 program in collaboration with their partner Lilly.
• Adrian Gottschalk noted that with their strong cash position and runway into 2027, they are poised to advance their clinical and preclinical pipeline.

Industry Context

Foghorn is operating in the competitive biotechnology sector, focusing on novel therapies targeting the chromatin regulatory system. Their approach to targeting previously undruggable proteins and their strategic collaboration with Lilly position them as a notable player in the field.

Comparison to Industry Standards

• Foghorn's approach to targeting the chromatin regulatory system is unique, as many companies focus on more traditional targets.
• The company's focus on protein degradation is in line with a growing trend in the industry, but their specific targets and methods are differentiated.
• The collaboration with Lilly is a significant validation of their technology and approach, as Lilly is a major player in the pharmaceutical industry.
• The cash runway into 2027 is a positive sign, as many biotech companies struggle with funding.
• The company's pipeline includes multiple first-in-class programs, which could provide a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and strong cash position, but concerned about the increased net loss.
• Employees may be motivated by the company's advancements and future prospects.
• Patients with SMARCA4 mutated cancers and AML may benefit from the company's novel therapies.
• The company's collaboration with Lilly may provide long-term benefits for all stakeholders.

Next Steps

• The company will continue the Phase 1 trial of FHD-909 in SMARCA4 mutated cancers.
• Topline data from the Phase 1 dose escalation trial of FHD-286 in combination with decitabine is expected by year-end 2024.
• IND-enabling studies for the Selective CBP degrader program are on track to begin by year-end 2024.
• The company will continue to advance its preclinical programs, including the Selective EP300 degrader and Selective ARID1B degrader programs.

Key Dates

Keywords

Foghorn Therapeutics, FHD-909, FHD-286, SMARCA2, SMARCA4, CBP degrader, EP300 degrader, ARID1B degrader, AML, NSCLC, Oncology, Chromatin Biology, Protein Degradation, Gene Traffic Control Platform